Anika Therapeutics Total Assets 2006-2021 | ANIK

Anika Therapeutics total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Anika Therapeutics Annual Total Assets
(Millions of US $)
2020 $366
2019 $331
2018 $279
2017 $283
2016 $240
2015 $236
2014 $193
2013 $156
2012 $142
2011 $133
2010 $129
2009 $129
2008 $96
2007 $79
2006 $68
2005 $63
Anika Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $353
2021-06-30 $363
2021-03-31 $362
2020-12-31 $366
2020-09-30 $416
2020-06-30 $441
2020-03-31 $399
2019-12-31 $331
2019-09-30 $320
2019-06-30 $287
2019-03-31 $307
2018-12-31 $279
2018-09-30 $269
2018-06-30 $265
2018-03-31 $284
2017-12-31 $283
2017-09-30 $273
2017-06-30 $265
2017-03-31 $247
2016-12-31 $240
2016-09-30 $231
2016-06-30 $223
2016-03-31 $214
2015-12-31 $236
2015-09-30 $223
2015-06-30 $208
2015-03-31 $198
2014-12-31 $193
2014-09-30 $185
2014-06-30 $179
2014-03-31 $174
2013-12-31 $156
2013-09-30 $157
2013-06-30 $148
2013-03-31 $141
2012-12-31 $142
2012-09-30 $135
2012-06-30 $136
2012-03-31 $133
2011-12-31 $133
2011-09-30 $130
2011-06-30 $131
2011-03-31 $129
2010-12-31 $129
2010-09-30 $130
2010-06-30 $124
2010-03-31 $127
2009-12-31 $129
2009-09-30 $96
2009-06-30 $96
2009-03-31 $95
2008-12-31 $96
2008-09-30 $88
2008-06-30 $88
2008-03-31 $83
2007-12-31 $79
2007-09-30 $81
2007-06-30 $76
2007-03-31 $69
2006-12-31 $68
2006-09-30 $69
2006-06-30 $66
2006-03-31 $63
2005-12-31 $63
2005-09-30 $63
2005-06-30 $60
2005-03-31 $59
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.556B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09